Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 19, 2025, Soligenix, Inc. (SNGX) announced that 50 patients are now enrolled in the ongoing Phase 3 FLASH2 Trial of HyBryte for the treatment of cutaneous T cell lymphoma (CTCL).</li><li>Enrollment of the 50th patient will allow for an interim analysis to occur in the second quarter of 2026.</li><li>Thus far, for the patients that have completed the trial, the overall blinded response rate is 48%.</li></ul>

On November 19, 2025, Soligenix, Inc. (SNGX) announced that 50 patients are now enrolled in the ongoing Phase 3 FLASH2 Trial of HyBryte for the treatment of cutaneous T cell lymphoma (CTCL).Enrollment of the 50th patient will allow for an interim analysis to occur in the second quarter of 2026.Thus far, for the patients that have completed the trial, the overall blinded response rate is 48%.

SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient  Interim Analysis in 2Q26